How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city

Jin-Ling Tang; Wei-Zhong Wang; Jian-Gang An; Yong-Hua Hu; Shi-Hua Cheng; Sian Griffiths
February 2010
International Journal of Epidemiology;Feb2010, Vol. 39 Issue 1, p244
Academic Journal
Background Current recommendations on drug treatment of hypertension for primary prevention of cardiovascular disease are primarily determined by the evidence of effectiveness, disregard the resources available and values of people, and recommend a universally fixed risk cutoff for initiating drug treatment. The guidelines may have over-estimated the willingness of the public to accept and pay for these drugs and a fixed cutoff may not fit all populations. Moreover, the public may have been misinformed and are unable to make the right decision even if they are consulted. We conducted this study to address these issues and to describe the gap between current policy and what the public truly want.


Related Articles

  • Factors influencing willingness to pay for healthcare. Aizuddin, Azimatun Noor; Sulong, Saperi; Mohamed Aljunid, Syed // BMC Public Health;2012, Vol. 12 Issue Suppl 2, p1 

    An abstract of the article "Factors influencing willingness to pay for healthcare," by Azimatun Noor Aizuddin, Saperi Sulong, and Syed Mohamed Aljunid is presented.

  • Cardiovascular.  // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p50 

    The article presents information on a clinical trial that was undertaken to test the efficacy and safety of the SPP635 drug in the treatment of hypertension. The trial had a double-blind, placebo-controlled, randomized, parallel design and it evaluated patients treated with a single dosage level...

  • Which factors influence willingness-to-pay for orthognathic treatment? Smith, A. S. A.; Cunningham, S. J. // European Journal of Orthodontics;Oct2004, Vol. 26 Issue 5, p499 

    The aims of this interview-based questionnaire study were to establish which factors influence willingness-to pay (WTP) for orthognathic treatment and to compare WTP values, from both members of the general public and orthognathic patients, with the actual cost of treatment, the hypothesis being...

  • Willingness to pay as a measure of health benefits. Bala, M.V.; Mauskopf, J.A.; Wood, L.L. // PharmacoEconomics;1999, Vol. 15 Issue 1, p9 

    In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method for valuing benefits in a CBA and describe how to obtain willingness-to-pay (WTP) measures of health benefits...

  • Study: Prevalence of resistant hypertension found in daily practice.  // Cardiology Today;May2011, Vol. 14 Issue 5, p33 

    This article discusses a study on the prevalence of resistant hypertension in patients treated for hypertension.

  • 346. Calcium-channel blockers protect more against stroke than against myocardial infarction. Staessen, J.A.; Wang, J-G.; Thijs, L. // Kidney;May/Jun2002, Vol. 11 Issue 3, p114 

    Provides information on a study which investigated cardiovascular protection and blood pressure reduction. Methodology; Results; Conclusion.

  • Blood-pressure screening and supervision in general practice. Barber, J.H.; Beevers, D.G.; Fife, R.; Hawthorne, V.M.; McKenzie, H.M.; Sinclair, R.G.; Simpson, R.J.; Stewart, G.M.; Williams, D.I. // British Medical Journal;3/31/1979, Vol. 1 Issue 6167, p843 

    Examines the screening and supervision of raised blood-pressure in general practice in Scotland. Reason for the prevalence of cardiovascular disease; Recommendation of the Working Party on Functional Integration of Patient Care in Hypertension for the recording of blood pressure of adults;...

  • A review of antihypertensive drug therapies. Smith, Haley // South African Pharmaceutical Journal;2014, Vol. 81 Issue 3, p21 

    High blood pressure (hypertension) is a global health burden affecting developed and developing countries, including South Africa. The high prevalence of hypertension worldwide contributes to the present and anticipated pandemic of cardiovascular disease (CVD), which is of particular concern in...

  • Aggressive BP control for cost savings seen as 'debatable.'.  // Cardiovascular Device Update;Feb2007, Vol. 13 Issue 2, p23 

    The article discusses research being done on the cost of hypertension treatment. It references a study by Caleb Alexander et al in the 2007 issue of the "Archives of Internal Medicine." Researcher found that high blood pressure is controlled better in the U.S. than in five Western European...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics